# Market Catalyst Decision Log

As of: 2026-05-13
Scope: open catalysts due or starting within 45 days; stale after 14 days.

## PFE - Pfizer Inc.

- Memo id: decision-demo-pfe-fda-2026
- Decision owner: TBD
- Decision status: draft
- Prepared on: 2026-05-13

### Thesis

- Thesis id: pharma-pipeline-reset
- Current impact: mixed
- Working thesis: Decision is mostly expected but clarifies launch timing.
- Decision question: Does the regulatory decision change the thesis for PFE?

### Catalyst

- Catalyst id: demo-pfe-fda-2026
- Event: regulatory_decision (2026-05-20..2026-05-24)
- Status: watching; confidence: 0.68; score: 87
- Urgency: high; review: stale; required action: verify_source

### Evidence

- Source ref: FDA calendar and PFE pipeline note
- Evidence checked at: 2026-04-28
- Evidence URLs:
  - https://example.com/fda-calendar
  - https://example.com/pfe-pipeline-update

### Scenarios

- bull: score 91; impact positive; date 2026-05-20; action verify_source:bull:stale; note: Approval expands pipeline credibility and supports forward revenue mix.
- base: score 87; impact mixed; date 2026-05-20..2026-05-24; action verify_source:base:stale; note: Decision is mostly expected but clarifies launch timing.
- bear: score 79; impact negative; date 2026-05-24; action verify_source:bear:stale; note: Delay or restrictive label pressures near-term sentiment.

### Broker Context

- View count: 2; target range: 31.00-39.00; average target: 35.00; stale views: 1
  - Harbor Life Sciences market perform 31.00 as of 2026-05-01; caveat: View depends on label breadth and launch timing after the decision window.; source: https://example.com/pfe-broker-harbor
  - Summit Research outperform 39.00 as of 2026-04-10; caveat: Model gives partial credit for approval but not a restrictive label.; source: https://example.com/pfe-broker-summit

### Watchlist Triggers

- [review_due] Review by 2026-05-13 before catalyst window 2026-05-20..2026-05-24. -> verify_source
- [event_window] Escalate if PFE confirms, delays, cancels, or changes the regulatory decision window. -> update_status_and_history
- [stale_review] Last review is stale by 15 days as of 2026-05-13. -> refresh_review_notes
- [source_check] Primary evidence changes, disappears, conflicts with another source, or lacks a dated update. -> verify_source
- [thesis_link] Bull/base/bear evidence changes the linked thesis 'pharma-pipeline-reset'. -> update_thesis_reference
- [exposure_change] Position size, portfolio weight, or risk budget changes before the event. -> refresh_exposure_context

### Decision Slots

- Pre-event decision: TBD
- Position action: TBD
- Risk limit or hedge: TBD
- Follow-up owner: TBD

### Post-Event Review

- Review due: 2026-05-24
- Outcome: TBD
- Thesis update: TBD
- Evidence delta: TBD
- Scenario accuracy: TBD
- Next action: TBD

## SPY - S&P 500 ETF Trust

- Memo id: decision-demo-fomc-june-2026
- Decision owner: TBD
- Decision status: draft
- Prepared on: 2026-05-13

### Thesis

- Thesis id: rates-duration-risk
- Current impact: mixed
- Working thesis: Statement broadly matches market-implied policy path.
- Decision question: Does the macro release change the thesis for SPY?

### Catalyst

- Catalyst id: demo-fomc-june-2026
- Event: macro_release (2026-06-17)
- Status: confirmed; confidence: 0.9; score: 83
- Urgency: medium; review: current; required action: monitor_date

### Evidence

- Source ref: FOMC public calendar
- Evidence checked at: missing
- Evidence URLs:
  - https://example.com/fomc-calendar

### Scenarios

- bull: score 90; impact positive; date 2026-06-17; action none; note: Policy language indicates lower real-rate pressure for duration assets.
- base: score 83; impact mixed; date 2026-06-17; action monitor_date; note: Statement broadly matches market-implied policy path.
- bear: score 72; impact negative; date 2026-06-17; action none; note: Inflation language reprices yields higher and weighs on multiples.

### Broker Context

- View count: 0; target range: none; average target: none; stale views: 0
  - No broker views recorded.

### Watchlist Triggers

- [review_due] Review by 2026-06-10 before catalyst window 2026-06-17. -> monitor_date
- [event_window] Escalate if SPY confirms, delays, cancels, or changes the macro release window. -> update_status_and_history
- [thesis_link] Bull/base/bear evidence changes the linked thesis 'rates-duration-risk'. -> update_thesis_reference
- [exposure_change] Position size, portfolio weight, or risk budget changes before the event. -> refresh_exposure_context

### Decision Slots

- Pre-event decision: TBD
- Position action: TBD
- Risk limit or hedge: TBD
- Follow-up owner: TBD

### Post-Event Review

- Review due: 2026-06-17
- Outcome: TBD
- Thesis update: TBD
- Evidence delta: TBD
- Scenario accuracy: TBD
- Next action: TBD

## NVDA - NVIDIA Corporation

- Memo id: decision-demo-nvda-computex-2026
- Decision owner: TBD
- Decision status: draft
- Prepared on: 2026-05-13

### Thesis

- Thesis id: ai-infrastructure-capex
- Current impact: positive
- Working thesis: Product roadmap details support existing accelerator growth expectations.
- Decision question: Does the product launch change the thesis for NVDA?

### Catalyst

- Catalyst id: demo-nvda-computex-2026
- Event: product_launch (2026-06-02)
- Status: scheduled; confidence: 0.74; score: 84
- Urgency: medium; review: current; required action: monitor_date

### Evidence

- Source ref: NVDA Computex keynote tracker
- Evidence checked at: 2026-05-09
- Evidence URLs:
  - https://example.com/nvidia-computex-keynote
  - https://example.com/channel-check-gpu-supply

### Scenarios

- bull: score 90; impact positive; date 2026-06-02; action none; note: Management confirms accelerated platform demand and shorter supply constraints.
- base: score 84; impact positive; date 2026-06-02; action monitor_date; note: Product roadmap details support existing accelerator growth expectations.
- bear: score 74; impact less_positive; date 2026-06-02; action none; note: Launch focuses on refresh timing without incremental demand signals.

### Broker Context

- View count: 2; target range: 1085.00-1320.00; average target: 1202.50; stale views: 1
  - Metro Capital Markets hold 1085.00 as of 2026-04-05; caveat: Older view predates the final Computex keynote agenda.; source: https://example.com/nvda-broker-metro
  - North Coast Securities buy 1320.00 as of 2026-05-10; caveat: Target assumes accelerator backlog converts into second-half revenue.; source: https://example.com/nvda-broker-north-coast

### Watchlist Triggers

- [review_due] Review by 2026-05-26 before catalyst window 2026-06-02. -> monitor_date
- [event_window] Escalate if NVDA confirms, delays, cancels, or changes the product launch window. -> update_status_and_history
- [thesis_link] Bull/base/bear evidence changes the linked thesis 'ai-infrastructure-capex'. -> update_thesis_reference
- [exposure_change] Position size, portfolio weight, or risk budget changes before the event. -> refresh_exposure_context

### Decision Slots

- Pre-event decision: TBD
- Position action: TBD
- Risk limit or hedge: TBD
- Follow-up owner: TBD

### Post-Event Review

- Review due: 2026-06-02
- Outcome: TBD
- Thesis update: TBD
- Evidence delta: TBD
- Scenario accuracy: TBD
- Next action: TBD
